Candidate vaccine viruses and potency testing reagents for influenza A(H1N1)

The WHO Global Influenza Surveillance Network closely monitors the antigenic and genetic evolution of emerging and circulating human influenza viruses. Countries are encouraged to share with WHO both their specimens/isolates for inclusion in the WHO influenza vaccine virus selection and development process, and other activities of public health importance.

Institutions, companies and other parties interested in developing vaccines to the novel influenza A (H1N1) virus are advised that the following candidate viruses are available.

Previous Summaries

• Summary of status of development and availability of A/California/7/2009 (H1N1)-like candidate vaccine viruses and potency testing reagents
  pdf, 151kb
  19 April 2011
• Summary of status of development and availability of A/california/7/2009(H1N1)-like candidate vaccine viruses and potency testing reagent
  pdf, 131kb
  07 March 2011
• Summary of status of development and availability of A/california/7/2009(H1N1)-like candidate vaccine viruses and potency testing reagent
  pdf, 105kb
  24 November 2010
• Summary of available candidate vaccine viruses for development of pandemic (H1N1) 2009 virus vaccines
  pdf, 94kb
  24 May 2010

• Availability of a new candidate reassortant vaccine virus for pandemic (H1N1) 2009 vaccine development
  18 March 2010
• Availability of a candidate international standard for antibody to A/California/7/2009 (H1N1)v-like viruses
  19 October 2009
• Availability of two new candidate reassortant vaccine viruses for pandemic (H1N1) 2009 virus vaccine development X-181 and X-181A
  14 September 2009
• Availability of a new candidate reassortant vaccine virus for pandemic (H1N1) 2009 virus vaccine development NIBRG-121xp
  6 August 2009
• Availability of four new candidate reassortant vaccine viruses for pandemic (H1N1) 2009 virus vaccine development IDCDC-RG18, IDCDC-RG20, IDCDC-RG22 and NIBRG-122
  22 July 2009
• Biocontainment requirements for vaccine production from and quality control of the reassortant candidate vaccine virus CBER-RG2
  21 July 2009
• Biocontainment requirements for vaccine production from and quality control of the reassortant candidate vaccine virus IVR-153
  6 July 2009
• Availability of a candidate reassortant vaccine virus for the novel influenza A (H1N1) vaccine development CBER-RG2
  24 June 2009
• Biocontainment requirements for vaccine production from and quality control of the reassortant vaccine candidate viruses IDCDC-RG15, NIBRG-121 and X-179A
  19 June 2009
• Gene sequences of the reassortant candidate vaccine viruses for the novel influenza A (H1N1)
  5 June 2009
• Availability of a candidate reassortant vaccine virus for the novel influenza A(H1N1) vaccine development IVR-153
  4 June 2009
• Availability of a candidate reassortant vaccine virus for the novel influenza A (H1N1) vaccine development NIBRG-121
  27 May 2009
• Availability of a candidate reassortant vaccine virus for the novel influenza A (H1N1) vaccine development X-179A
  27 May 2009
• Availability of a candidate reassortant vaccine virus for the novel influenza A (H1N1) vaccine development: IDCDC-RG15
  27 May 2009